Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $3.33 billion. The enterprise value is $3.13 billion.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 63.22 million shares outstanding. The number of shares has increased by 5.76% in one year.
| Current Share Class | 63.22M |
| Shares Outstanding | 63.22M |
| Shares Change (YoY) | +5.76% |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 78.64% |
| Float | 46.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.69 |
| Forward PS | 17.56 |
| PB Ratio | 157.35 |
| P/TBV Ratio | 214.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.69.
| Current Ratio | 3.24 |
| Quick Ratio | 2.94 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.89 |
Financial Efficiency
Return on equity (ROE) is -155.91% and return on invested capital (ROIC) is -59.75%.
| Return on Equity (ROE) | -155.91% |
| Return on Assets (ROA) | -45.78% |
| Return on Invested Capital (ROIC) | -59.75% |
| Return on Capital Employed (ROCE) | -95.93% |
| Revenue Per Employee | $459,809 |
| Profits Per Employee | -$934,883 |
| Employee Count | 283 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 0.98 |
Taxes
In the past 12 months, RYTM has paid $346,000 in taxes.
| Income Tax | 346,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.97% in the last 52 weeks. The beta is 2.30, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.30 |
| 52-Week Price Change | +21.97% |
| 50-Day Moving Average | 55.18 |
| 200-Day Moving Average | 52.16 |
| Relative Strength Index (RSI) | 47.94 |
| Average Volume (20 Days) | 521,734 |
Short Selling Information
The latest short interest is 4.71 million, so 7.45% of the outstanding shares have been sold short.
| Short Interest | 4.71M |
| Short Previous Month | 5.15M |
| Short % of Shares Out | 7.45% |
| Short % of Float | 10.03% |
| Short Ratio (days to cover) | 8.39 |
Income Statement
In the last 12 months, RYTM had revenue of $130.13 million and -$264.57 million in losses. Loss per share was -$4.34.
| Revenue | 130.13M |
| Gross Profit | 116.76M |
| Operating Income | -265.50M |
| Pretax Income | -258.09M |
| Net Income | -264.57M |
| EBITDA | -263.94M |
| EBIT | -265.50M |
| Loss Per Share | -$4.34 |
Full Income StatementBalance Sheet
The company has $320.57 million in cash and $113.75 million in debt, giving a net cash position of $206.82 million or $3.27 per share.
| Cash & Cash Equivalents | 320.57M |
| Total Debt | 113.75M |
| Net Cash | 206.82M |
| Net Cash Per Share | $3.27 |
| Equity (Book Value) | 164.55M |
| Book Value Per Share | 0.35 |
| Working Capital | 258.68M |
Full Balance SheetCash Flow
| Operating Cash Flow | -113.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | -113.88M |
| FCF Per Share | -$1.80 |
Full Cash Flow StatementMargins
Gross margin is 89.73%, with operating and profit margins of -204.04% and -200.27%.
| Gross Margin | 89.73% |
| Operating Margin | -204.04% |
| Pretax Margin | -200.00% |
| Profit Margin | -200.27% |
| EBITDA Margin | -202.83% |
| EBIT Margin | -204.04% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.76% |
| Shareholder Yield | -5.76% |
| Earnings Yield | -7.92% |
| FCF Yield | -3.41% |
Dividend DetailsAnalyst Forecast
The average price target for RYTM is $68.58, which is 30.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $68.58 |
| Price Target Difference | 30.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 59.09% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 2.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.25 |
| Piotroski F-Score | 3 |